Literature DB >> 8691592

[Sinus bradyarrhythmia during administration of all-trans retinoic acid in a patient with acute promyelocytic leukemia].

K Maruhashi1, H Wada, M Taniguchi, S Koizumi.   

Abstract

A case of acute promyelocytic leukemia (APL) complicated by sinus bradyarrhythmia during the course of all-trans retinoic acid (ATRA) administration is reported. A 3-year-old boy was admitted for evaluation of petechiae and APL was diagnosed. He was initially treated with 45 mg/m2 of ATRA without success, and a complete remission was achieved when the dose was increased to 135 mg/m2. Sinus bradyarrhythmia was first recognized 3 days after the induction therapy with ATRA. It did not disappear even when the patient stopped taking the medication. However, the arrhythmia tended to be augmented whenever he received ATRA again. Close observation of his cardiac condition was mandatory to continue ATRA as an integral part of the therapy for APL, combined with multidrug chemotherapy including anthracyclines, which themselves are potentially toxic to myocardium. In conclusion, the present case revealed the possibility that ATRA therapy induces sinus node arrhythmia, or that it can potentiate preexisting node dysfunctions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691592

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  3 in total

1.  Bradycardia following retinoic acid differentiation syndrome in a patient with acute promyelocytic leukaemia.

Authors:  Andrew McGregor; Erin Hurst; Stephen Lord; Gail Jones
Journal:  BMJ Case Rep       Date:  2012-07-09

2.  Bradycardia during Induction Therapy with All-trans Retinoic Acid in Patients with Acute Promyelocytic Leukemia: Case Report and Literature Review.

Authors:  Pin-Zi Chen; Yee-Jen Wu; Chien-Chih Wu; Yu-Wen Wang
Journal:  Case Rep Hematol       Date:  2018-06-07

3.  Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis.

Authors:  Valeria Ferla; Mariarita Sciumé; Umberto Gianelli; Luca Baldini; Nicola Stefano Fracchiolla
Journal:  Explor Target Antitumor Ther       Date:  2020-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.